StockNews.AI
IRIX
StockNews.AI
5 days

Iridex to Report Fourth Quarter and Full Year 2024 Financial Results on March 27, 2025

1. IRIDEX to release Q4 and FY 2024 financial results on March 27, 2025. 2. Conference call scheduled for 2:00 p.m. PT / 5:00 p.m. ET. 3. IRIDEX specializes in laser-based medical systems for eye conditions. 4. Their products include treatments for glaucoma and diabetic macular edema. 5. MicroPulse® technology offers safe treatments for eye diseases.

4 mins saved
Full Article

FAQ

Why Neutral?

While the upcoming earnings report is pivotal, no major surprises are anticipated.

How important is it?

The earnings report is crucial for investor sentiment but lacks catalysts for major movement.

Why Short Term?

Earnings releases typically impact stock prices shortly after reports are made public.

Related Companies

ALDXAEYEOCUL
March 13, 2025 17:00 ET  | Source: IRIDEX Corporation MOUNTAIN VIEW, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today announced the Company plans to release financial results for the fourth quarter and full year 2024 and provide a business update after the close of trading on Thursday, March 27, 2025. The Company’s management team will host a corresponding conference call beginning at 2:00 p.m. PT / 5:00 p.m. ET. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com. About Iridex Corporation Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com. MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved. Investor Relations Contact:Philip TaylorGilmartin Groupinvestors@iridex.com

Related News